A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Recruiting · Phase 1, Phase 2 · NCT07215234
Conditions: Geographic Atrophy
At a glance
- Research payments reported, 2025
- $61,692
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 104
About the trial
- Sponsor
- Sanofi
- Tested
- SAR446597 (drug), Sham Comparator (drug)
- Dates
- Started 2025-10-09; completion 2032-07-22
- Results posted
- Not yet
This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). The core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase. The treatment is a one-time intravitreal injection of SAR446597 (or sham as applicable in Part II).
From ClinicalTrials.gov, last updated 2026-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $61,692 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Benjamin B. Bakall, M.D., PH.D. Retina Specialist · Phoenix, AZ
- Veeral Sheth, M.D. Ophthalmology · Oak Forest, IL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Univ. of Vermont - Fletcher Allen Health Care, VT $32,010
- Doctrials Llc $29,682
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.